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A B S T R A C T
Background: There are no nuclear cardiology reports indicating the prediction of prognosis based on
ischemic reduction after revascularization in Japanese patients with coronary artery disease (CAD). We
aimed to evaluate quantitatively ischemia using myocardial perfusion single photon emission computed
tomography (SPECT) before and after treatment such as revascularization and to determine a
relationship between the ischemic reduction and the incidence of major cardiac events (MCEs) after the
treatment in patients with CAD.
Methods: We retrospectively investigated 513 patients who underwent rest 201Tl and stress 99mTc-
tetrofosmin myocardial perfusion SPECT between October 2004 and March 2011 and who had a
signiﬁcant stenosis with 75% or greater narrowing of the coronary arterial diameter detected by coronary
angiography performed after conﬁrmation of 5% ischemia with SPECT. The patients underwent the
treatment including revascularization and medication and thereafter were re-evaluated with SPECT
during a chronic phase and followed up to conﬁrm prognosis for 1 year. The follow-up period was
33.4  16.4 months. The endpoint was the incidence of the MCEs consisting of cardiac death, non-fatal
myocardial infarction, and unstable angina pectoris.
Results: During the follow-up, 45 patients experienced MCEs comprising cardiac death (n = 13), non-
fatal myocardial infarction (n = 3), and unstable angina pectoris (n = 29). The multivariate Cox
proportional hazards regression model analysis for the risk of the MCEs showed the changes in the
summed difference score % (p = 0.0102) and the stress left ventricular ejection fraction after the
treatment (p = 0.0146) as signiﬁcant independent variables. The incidence of the MCEs signiﬁcantly
decreased in the patients with 5% ischemic reduction than in the patients without 5% ischemic
reduction and in the patients without residual ischemia than in the patients with the residual ischemia.
Conclusion: Myocardial ischemic reduction detected by nuclear cardiology leads to a decrease in MCE
rates after treatment in Japanese patients with CAD.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Myocardial perfusion single photon emission computed to-
mography (SPECT) has been well recognized as a useful imaging
method for the prediction of future cardiac events in patients with
known or suspected coronary artery disease (CAD) since the
reports of Hachamovitch et al. [1,2].* Corresponding author at: Department of Cardiology, Nihon University School of
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http://dx.doi.org/10.1016/j.jjcc.2014.06.015
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsIn Japan, myocardial perfusion SPECT has also commonly been
used to predict cardiac events in patients with CAD. Risk
stratiﬁcation of cardiac events by nuclear cardiology has been
demonstrated in some large-scale prognostic studies including
the multicenter prospective Japanese Assessment of Cardiac
Events and Survival Study in patients with ischemic heart
disease (J-ACCESS) [3], in asymptomatic patients with type 2
diabetes (J-ACCESS 2) [4], and patients with chronic kidney
disease (J-ACCESS 3) [5], and another single-center large-scale
prospective study [6]. In those studies, patients who underwent
revascularization within 60 days after baseline SPECT were
excluded from assessment and the prognosis of patients with CAD
was predicted based on the baseline SPECT. However, it is also reserved.
Fig. 1. Timing of nuclear cardiology, coronary angiography and revascularization.
SPECT, single photon emission computed tomography; CAG, coronary angiography;
Revasc, revascularization; mo, month.
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revascularization.
The COURAGE (clinical outcomes utilizing revascularization
and aggressive drug evaluation) trial [7] was conducted to compare
cardiac event rates between patients with stable angina pectoris
undergoing percutaneous coronary intervention (PCI) with opti-
mal medical treatment and those receiving optimal medical
treatment alone in the USA. The incidence of cardiac death and
non-fatal myocardial infarction (MI) was 19.0% in the patients with
PCI and 18.5% in those without PCI, and long-term prognosis was
similar between the two patient populations. However, a nuclear
sub-study [8] of the COURAGE trial in 314 patients who underwent
SPECT before and after PCI provided interesting data, namely,
signiﬁcant ischemic reduction was observed in patients treated
with optimal medication adding PCI. Prognosis was more favorable
in the patients with at least 5% ischemic reduction after PCI than
without at least 5% ischemic reduction after PCI and also with
residual ischemia approaching zero.
Assessment of myocardial ischemia with SPECT before and after
PCI is considered to be useful for the prediction of prognosis after
PCI on the basis of the results from the nuclear sub-study of the
COURAGE trial. However, the evaluation of ischemic reduction
after PCI was not the primary objective in the study and was based
on sub-analysis; the number of patients evaluated was small and
the patients had relatively mild ischemia with a pre-treatment
ischemic total perfusion deﬁcit being approximately 8%. In
addition, because the study subjects were patients with stable
effort angina, the data obtained from the nuclear sub-study cannot
be applied to patients with history of MI and more severe cases,
who should be cared for in usual clinical practice. Furthermore,
there are no reports indicating such data in Japanese patients. We,
therefore, have conducted this retrospective prognostic study in
Japanese patients with CAD to evaluate quantitatively myocardial
ischemia using SPECT before and after revascularization and to
determine a relationship between the ischemic reduction and the
incidence of cardiovascular events after the revascularization.
Materials and methods
The institutional review board of Nihon University Itabashi
Hospital approved this study, which proceeded in accordance with
the ethical standards established in the 1964 Declaration of
Helsinki. All study participants provided written informed consent
prior to inclusion in this study.
Patient population
We retrospectively investigated 513 patients with CAD who
underwent rest 201Tl and stress 99mTc-tetrofosmin myocardial
perfusion SPECT [6,9–13] at Nihon University Itabashi Hospital
between October 2004 and March 2011 and who had a signiﬁcant
stenosis with 75% or greater narrowing of the coronary arterial
diameter detected by coronary angiography (CAG) performed after
conﬁrmation of at least 5% ischemia by the SPECT. The patients
underwent treatment including revascularization and medication,
and thereafter were re-evaluated with the SPECT during a chronic
phase and followed up to conﬁrm prognosis for at least 1 year. The
interval between the ﬁrst SPECT and the CAG was 1.7  3.4 months,
that between the CAG and revascularization was 1.1  4.5 months
and that between the revascularization and the second SPECT was
10.3  8.5 months. The second SPECT was performed at 14.1  11.3
months after the ﬁrst SPECT (Fig. 1). We excluded patients aged 20
years, those with hypertrophic or dilated cardiomyopathy, those with
serious valvular heart disease, those with heart failure with class III or
higher New York Heart Association (NYHA) functional classiﬁcation,
and those with less than 5% ischemia detected by the ﬁrst SPECT.Follow-up examinations were based on medical records for patients
who periodically attended the hospital and responses to a posted
questionnaire for patients who did not. The follow-up was successful
for 483 patients (94%), but failed for the remaining 30 patients. Data
from all 483 patients were ﬁnally included in the analysis.
Electrocardiogram-gated dual-isotope myocardial perfusion SPECT
The procedure of rest 201Tl and stress 99mTc-tetrofosmin
electrocardiogram (ECG)-gated myocardial perfusion SPECT was
performed according to a protocol previously reported [6,9–13]. All
patients received an intravenous (i.v.) injection of 201Tl (111 MBq)
and a 16-frame gated SPECT imaging was initiated 10 min after
injection during rest. Then an i.v. injection of 99mTc-tetrofosmin
(740 MBq) was performed under stress induced by ergometer
exercise in 23% of the patients or by adenosine triphosphate in 77%.
Sixteen-frame gated SPECT image acquisition was initiated 30 min
after the exercise or 30–60 min after the adenosine triphosphate
stress. The acquisition was performed in a supine position and
subsequently in a prone position. No attenuation or scatter
correction was used. Twelve-lead ECG was monitored continu-
ously during stress tests. Heart rate and blood pressure were
recorded at baseline and every minute for at least 3 min after the
stress.
The projection data over 3608 were obtained with 64  64
matrices and a circular orbit. A triple-detector SPECT system
equipped with low-energy high-resolution collimators was used
(Toshiba, GCA9300A, Tokyo, Japan).
SPECT images were reconstructed from the data with a data
processor (Philips North America, JETStream Workspace 3.0,
Andover, MA, USA) combined with a Butterworth ﬁlter of 201Tl
(order 5; cut-off frequency 0.42 cycles/cm), that of 99mTc (order 5;
cut-off frequency 0.44 cycles/cm) and a ramp ﬁlter.
SPECT image interpretation
The SPECT images were divided into 20 segments [14] on three
short-axes (distal, mid, basal) and one on vertical long-axis (mid)
slices, and the tracer uptake of each segment was visually scored
using a 5-point scale (0: normal; 1: slight reduction of uptake; 2:
moderate reduction of uptake; 3: severe reduction of uptake; and
4: absence of uptake). The sum total of the scores of 20 segments in
the stress and rest images provided the summed stress score (SSS)
and the summed rest score (SRS), respectively. The summed
difference score (SDS) was calculated as the difference between
the SSS and SRS. The respective summed scores were converted
into percent of the total myocardium (visual % myocardium).
Visual % myocardium was derived from a summed score divided
by the maximum potential score (4  20) and multiplied by 100.
Table 1
Characteristics of patients with and without major cardiac events.
Major car-
diac event
(+)
Major cardi-
ac event ()
p value
N = 45 N = 438
Male patients 38 84% 352 80% 0.6438
Age 67  11 67  9 0.4354
Typical chest pain 16 36% 165 38% 0.9065
History of MI 24 53% 171 39% 0.0889
History of revascularization 28 62% 208 47% 0.0843
Hypertension 34 76% 345 79% 0.7576
Diabetics 25 56% 208 47% 0.3818
Hyperlipidemia 19 42% 256 58% 0.0530
Smoking 18 40% 161 37% 0.7897
Aspirin 43 96% 423 97% 0.9432
Statins 22 49% 263 60% 0.1971
b-blockers 14 31% 162 37% 0.5371
Ca-antagonists 25 56% 208 47% 0.3818
Nitrates 17 38% 182 42% 0.7407
ARB 22 49% 217 50% 0.9419
ACE inhibitor 7 16% 37 8% 0.1916
eGFR 52.9  27.3 59.0  23.3 0.0987
Angiographic CAD
1 Vessel 10 22% 150 34% 0.1427
2 Vessels 19 42% 136 31% 0.1735
3 Vessels 16 36% 152 35% 0.9611
Treatment
PCI 34 76% 328 75% 0.9347
CABG 1 2% 40 9% 0.1926
Medication 10 22% 70 16% 0.3888
MI, myocardial infarction; ARB, angiotensin receptor blocker; ACE, angiotensin-
converting enzyme; eGFR, estimated glomerular ﬁltration rate; CAD, coronary
artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery
bypass grafting.
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SDS% was 0% after treatment was deﬁned as ‘no residual ischemia’
and when SDS% was 1% after treatment was deﬁned as ‘residual
ischemia’. A change in SDS% (DSDS%) was a difference between
SDS% by the ﬁrst and second SPECT. The visual semi-quantitative
scoring was performed by two independent expert interpreters
who were not provided with patient’s clinical information. Cohen’s
kappa (k), which was calculated to determine the inter-observer
variability for the summed defect score, was 0.92, indicating very
good reproducibility.
Patient follow-up
All the 483 patients were followed up for at least 1 year
(33.4  16.4 months) after the second SPECT. The study endpoint was
the incidence of major cardiac events (MCEs) during the follow-up,
consisting of cardiac death, non-fatal MI, and unstable angina pectoris
(UAP) identiﬁed from medical records or from responses to a posted
questionnaire. When a patient had several cardiac events, only the
ﬁrst event was taken as the follow-up endpoint.
Statistical analysis
Continuous variables were calculated as means and standard
deviations. Intergroup comparisons of continuous and categorical
variables were achieved using an unpaired t test and the x2 test,
respectively. A paired t-test was used to analyze the signiﬁcance of
difference of the summed defect scores and of left ventricular
function on the quantitative gated SPECT before and after the
treatment. Univariate analyses proceeded using a Cox proportional
hazards model. Multivariate analyses proceeded using a stepwise
Cox proportional hazards model. Kaplan–Meier survival analyses
were estimated for patients with and without 5% ischemic
reduction and for patients with and without residual ischemia
after the treatment. Receiver operating characteristic (ROC)
analysis was employed to evaluate sensitivity and speciﬁcity for
the detection of ischemic reduction. All data were analyzed using
MedCalc Software Version 12.6.1.0 (Mariakerke, Belgium). A p
value of <0.05 was considered statistically signiﬁcant.
Results
Cardiac event rates and patient characteristics
During the follow-up, 45 (9.3%) of 483 patients experienced
MCEs including cardiac death (n = 13), non-fatal MI (n = 3), and
UAP (n = 29). Table 1 summarizes the characteristics of the
patients with and without MCEs. The proportions of patients
treated with medications including aspirin, statins, b-blockers,
calcium antagonists, nitrates, angiotensin II receptor blockers, or
angiotensin-converting enzyme inhibitors were similar between
two groups with and without MCEs. The proportions of patients
with a typical chest pain, those with a history of MI or
revascularization, and those with hypertension, diabetes melli-
tus, hyperlipidemia, or smoking habit were similar between
the two groups. Also, estimated glomerular ﬁltration rates and
the severity of CAD detected by CAG were similar between the
two groups. The proportions of patients undergoing PCI were 76%
(34/45) in the group with MCEs and 75% (328/438) in the group
without MCEs. One of the patients with MCEs and 40 of the
patients without MCEs underwent coronary artery bypass
grafting. Remaining patients (10 and 70 in the groups with and
without MCEs, respectively) received medication alone, mainly by
reason of an inappropriate lesion for revascularization or
operator’s decision.Visual % myocardium and left ventricular function
Table 2 summarizes the changes in visual % myocardium (SSS%,
SRS%, and SDS%) for myocardial defects detected by the SPECT and
in left ventricular ejection fraction (LVEF), left ventricular end-
diastolic volume (LVEDV), and left ventricular end-systolic volume
(LVESV) estimated with the quantitative gated SPECT before and
after the treatment in the patients with and without MCEs. The
SSS% and SDS% signiﬁcantly improved after the treatment in the
two groups. The magnitude of the DSDS% was signiﬁcantly larger
in the patients without MCEs than with MCEs (8.3  8.9 vs.
4.4  7.1; p = 0.0037, Fig. 2). No signiﬁcant improvement was
observed in the SRS% in either group. No changes in the left
ventricular function parameters were observed after the treatment in
the patients with MCEs. In contrast, the patients without MCEs had
signiﬁcant improvement of the left ventricular function after the
treatment (p < 0.0001 for LVEF, p  0.0469 for LVEDV, p  0.0062 for
LVESV).
ROC analysis for detection of MCEs by changes in SDS%
ROC analysis indicated that an optimal cut-off value of changes
in the SDS% (DSDS) was 5%. The sensitivity and speciﬁcity for
detection of MCEs were 65% and 56%, respectively (Fig. 3). On the
basis of this result, the frequency of 5% ischemic reduction was
signiﬁcantly different between the patients with and without
MCEs, being 44% (20/45) and 67% (292/438), respectively
(p = 0.0050).
Prediction of MCEs
Table 3 summarizes the results of univariate Cox proportional
hazards regression model analysis with MCE rates as the
dependent variable. Signiﬁcant variables associated with increased
Table 2
Visual segmental scores for myocardial defects and left ventricular functions before and after the treatmenta in the patients with and without major cardiac events.
Major cardiac event (+) p value Major cardiac event () p value
N = 45 N = 438
Before After Before After
SSS% 18.2  11.4 14.0  11.1 0.0025 19.5  11.0 11.5  11.8 <0.0001
SRS% 6.0  7.4 6.1  8.6 0.8580 5.3  8.1 5.7  9.1 0.1458
SDS% 12.3  6.2 7.9  7.3 0.0002 14.2  7.5 5.9  6.4 <0.0001
0% 0 0% 6 13% 0 0% 148 34%
1–4.9% 0 0% 9 20% 0 0% 55 13%
5% 45 100% 30 67% 438 100% 235 54%
LVEF
Rest 53.7  13.7 53.7  14.1 0.9842 56.9  13.9 58.8  14.0 <0.0001
Post stress 50.7  13.4 51.5  13.4 0.5796 54.1  13.5 57.2  13.6 <0.0001
LVEDV
Rest 97.2  51.4 96.1  44.4 0.7924 93.0  42.9 91.0  42.7 0.0469
Post stress 117.2  54.0 112.8  50.6 0.3732 110.4  47.3 105.3  47.4 <0.0001
LVESV
Rest 50.9  44.7 49.8  41.1 0.7594 44.9  36.4 42.4  36.7 0.0062
Post stress 64.3  48.2 61.1  46.9 0.4245 55.9  40.8 50.2  40.1 <0.0001
SSS, summed stress score; SRS, summed rest score; SDS, summed difference score; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume;
LVESV, left ventricular end-systolic volume.
a The treatment consists of percutaneous coronary intervention, coronary artery bypass grafting, and medication.
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after the treatment (p = 0.0429), the DSDS% (p = 0.0039), 5%
ischemic reduction (p = 0.0108), rest and stress LVEF after the
treatment (p = 0.0117 and p = 0.0046) and stress LVESV after the
treatment (p = 0.0428).Fig. 2. Comparison of ischemic reduction (DSDS%) between patients with and
without major cardiac events (cardiac death, non-fatal myocardial infarction, and
unstable angina pectoris). SDS, summed difference score; MCE, major cardiac event.
Fig. 3. Receiver operating characteristic curves for detection of major cardiac events
by changes in summed difference score%. Major cardiac event, cardiac death, non-
fatal myocardial infarction, and unstable angina pectoris.The multivariate Cox proportional hazards regression model
analysis for risk of the MCE showed the DSDS% (p = 0.0102) and
the stress LVEF after the treatment (p = 0.0146) as signiﬁcant
independent variables (Table 4).
Incidence of MCEs based on ischemic reduction or residual ischemia
after treatment
Fig. 4 illustrates Kaplan–Meier curves of the MCE-free survival
for the patients with (n = 312) and without (n = 171) 5% ischemic
reduction after the treatment. The incidence of the MCEsTable 3
Univariate Cox proportional hazards regression analysis.
Chi-square Hazard
ratio
95% Conﬁdence
interval
p value
Age 0.386 1.0106 0.9775–1.0447 0.5377
Male patients 0.413 1.2944 0.5783–2.8974 0.5323
History of MI 2.028 1.5509 0.8519–2.8236 0.1532
History of revascularization 4.041 1.8551 1.0087–3.4117 0.0480
Hypertension 0.006 1.0225 0.5822–1.7958 0.9386
Diabetes mellitus 1.805 1.5064 0.8280–2.7407 0.1818
Hyperlipidemia 3.901 0.5479 0.3007–0.9985 0.0506
Smoking 0.001 0.9989 0.5428–1.8385 0.9973
Statin use 2.700 0.5822 0.2995–1.1317 0.1125
SSS% before treatment 0.501 0.9901 0.9627–1.0182 0.4866
SRS% before treatment 0.284 1.0096 0.9755–1.0450 0.5862
SDS% before treatment 3.075 0.9599 0.9146–1.0074 0.0982
SSS% after treatment 1.976 1.0171 0.9945–1.0401 0.1417
SRS% after treatment 0.234 1.0078 0.9776–1.0389 0.6198
SDS% after treatment 3.655 1.0430 1.0015–1.0861 0.0429
DSDS% 9.212 0.9413 0.9035–0.9806 0.0039
5% Ischemic reduction 6.497 0.4616 0.2556–0.8336 0.0108
Rest LVEF after treatment 5.879 0.9760 0.9579–0.9945 0.0117
Rest LVEDV after treatment 1.189 1.0036 0.9975–1.0097 0.2513
Rest LVESV after treatment 2.176 1.0052 0.9989–1.0116 0.1086
Stress LVEF after treatment 7.598 0.9716 0.9525–0.9910 0.0046
Stress LVEDV after treatment 1.767 1.0038 0.9985–1.0091 0.1584
Stress LVESV after treatment 3.403 1.0058 1.0002–1.0113 0.0428
eGFR 1.617 0.9919 0.9799–1.0041 0.1955
The treatment mentioned in this table consists of percutaneous coronary
intervention, coronary artery bypass grafting, and medication. MI, myocardial
infarction; SSS, summed stress score; SRS, summed rest score; SDS, summed
difference score; DSDS%, a difference between SDS% by the ﬁrst and second
single photon emission computed tomography; LVEF, left ventricular ejection
fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular
end-systolic volume; eGFR, estimated glomerular ﬁltration rate.
Table 4
Multivariate Cox proportional hazards regression analysis.
Hazard ratio 95% Conﬁdence
interval
p value
DSDS% 0.9480 0.9104–0.9872 0.0102
Stress LVEF after treatment 0.9744 0.9544–0.9948 0.0146
The treatment mentioned in this table consists of percutaneous coronary
intervention, coronary artery bypass grafting, and medication SDS, summed
difference score; DSDS%, a difference between SDS% by the ﬁrst and second
single photon emission computed tomography; LVEF, left ventricular ejection
fraction.
Fig. 5. Kaplan–Meier curves of major cardiac event-free survival for the patients
with and without residual ischemia after treatment. Major cardiac event, cardiac
death, non-fatal myocardial infarction, and unstable angina pectoris.
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reduction than in the patients without 5% ischemic reduction
(p = 0.0090).
Fig. 5 illustrates Kaplan–Meier curves of the MCE free survival
for the patients with (n = 329) and without (n = 154) residual
ischemia after the treatment. The incidence of the MCEs
signiﬁcantly decreased in the patients without residual ischemia
than in the patients with residual ischemia (p = 0.0088).
Typical SPECT images
Fig. 6 shows typical polar maps obtained in a patient with
ischemic reduction who had a good prognosis (a) and a patient
without ischemic reduction who had a poor prognosis (b).
The patient (a) was a 62-year-old male with stable effort angina.
The ﬁrst SPECT showed extensive ischemia in the region of the left
anterior descending artery (LAD). He underwent CAG, which
evidenced 99% stenosis in the proximal region of the LAD and 75%
stenosis in the middle region of the left circumﬂex artery (LCX),
and underwent PCI for the stenosis in the LAD. No ischemia was
detected in the LAD region by the second SPECT. The ischemic
reduction (DSDS%) was 38.8% and no residual ischemia was
observed. Thereafter, he experienced no cardiac events and had a
good prognosis.
The patient (b) was a 76-year-old male with old MI. The ﬁrst
SPECT showed infarction and peri-infarction ischemia in the LCX
region. CAG evidenced 100% stenosis in the middle region of the
LCX and 90% stenosis in the distal region of the right coronary
artery. Therefore, he underwent PCI for the stenosis in the LCX, but
the results of the PCI for the LCX lesion were unsuccessful. The
second SPECT showed the same ﬁnding consisting of infarction and
ischemia as detected by the ﬁrst SPECT. The DSDS% was 1.2% andFig. 4. Kaplan–Meier curves of major cardiac event-free survival for the patients
with and without 5% ischemic reduction after the treatment. Major cardiac event,
cardiac death, non-fatal myocardial infarction, and unstable angina pectoris.the residual ischemia was 13.8%. Subsequently he was followed up
with medication but had cardiac death.
Discussion
This is the ﬁrst report in Japan, demonstrating that prediction of
future cardiac events based on ischemic reduction after revascu-
larization and nuclear cardiology in patients with CAD. The
patients experienced 5% ischemic reduction after treatment
including revascularization and medication had signiﬁcantly lower
incidence of MCEs in comparison with the patients without
ischemic reduction. The left ventricular function evaluated with
the quantitative gated SPECT signiﬁcantly improved after the
treatment in the patients without MCEs than with MCEs. Also, the
ischemic reduction and stress LVEF after the treatment were
signiﬁcant independent variables for prediction of future MCEs.
In an exploratory analysis, an optimal cut-off value of the post-
treatment SDS% was 0% on the basis of the ROC curve indicating
relationship between the SDS% and cardiac events after the
treatment. As a natural result, a survival rate estimated by Kaplan–
Meier analysis was signiﬁcantly higher in patients without (0%)
residual ischemia than with (>1%) residual ischemia after the
treatment. Ideal revascularization is to result in complete
elimination of residual ischemia. However, it is hard to completely
remove ischemia in multivessel disease because re-evaluation
with SPECT indicates a high probability of residual ischemia after
treatment of the primary lesion. In the present results, as shown in
Table 2, the proportion of patients with the post-treatment
SDS% = 0% was only 34% in the group without MCEs and that of
those with the post-treatment SDS%  5% was not statistically
different between the groups with and without MCEs (67% and
54%, p = 0.1302). Consequently, a signiﬁcant variable predicting
MCEs in patients with >1% residual ischemia should be further
investigated in a future study.
In the present study, 5% ischemic reduction resulted in the
improvement of prognosis in a larger number of patients than that
in COURAGE Nuclear Sub-study [6]. The ‘‘5%’’ was also a cut-off
value demonstrated in the COURAGE Nuclear Sub-study. There-
fore, it may be a consistent target value for the reduction of
ischemia where revascularization is performed to improve
prognosis in any racial patient with CAD. In addition, the
pre-treatment mean ischemic % myocardium in our study patients
was 14% as the SDS% and larger than that in the COURAGE Nuclear
Fig. 6. Typical polar maps in a patient with ischemic reduction who had a good prognosis (a) and a patient without ischemic reduction who had a poor prognosis (b).
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achievement of 5% ischemic reduction by treatment such as
revascularization and elimination of residual ischemia led to
avoidance of cardiovascular events even in patients with severe
ischemia.
Fractional ﬂow reserve (FFR), which is a physiological ischemic
variable, is used for the determination of therapeutic strategy and
the prediction of prognosis like SPECT. The FAME (Fractional Flow
Reserve vs. Angiography for Multivessel Evaluation) study [15] was
conducted to compare the rate of death, non-fatal MI, or repeat
revascularization at 1 year in patients with multivessel CAD who
underwent PCI with implantation of drug-eluting stents guided by
angiography alone or guided by FFR measurements in addition to
angiography, to obtain results such that routine measurement of
FFR signiﬁcantly decreased the incidence of the adverse cardiac
events. In the FAME 2 study [16], the risk of adverse cardiac events,
especially urgent repeat revascularization, signiﬁcantly more
reduced in patients with stable multivessel CAD who underwent
PCI with implantation of drug-eluting stents guided by FFR
measurements and optimal medical treatment than those who
underwent optimal medical treatment alone. The other random-
ized trial (DEFER study) [17] was conducted to evaluate whether
FFR could determine the appropriateness of PCI in patients for
whom PCI was planned and who had no evidence of ischemia. The
PCI was an appropriate treatment and markedly improved
functional class in patients with FFR  0.75 before the planned
intervention but did not beneﬁt those with FFR > 0.75.
In all the three studies mentioned above, adoption of
revascularization and prediction of prognosis were based on
physiological evaluation of stenosis with FFR. The procedure of the
FFR estimation was hard to be conducted in all patients intended to
undergo PCI because that was invasive. Actually, the FFR was not
estimated in patients with stenosis being anatomically difﬁcult for
a pressure wire to be inserted and the FFR was incorrect if one
vessel had multiple stenoses. In addition, the procedure for the FFR
determination has a risk of life-threatening events such as
perforation of coronary arteries because of the invasive procedure.In contrast, SPECT allows non-invasive assessment of ischemic
reduction and residual ischemia before and after PCI and there is
evidence of its use for the prediction of prognosis of patients with
CAD [1–6]. Therefore, the results from the present nuclear
cardiology study would lead to high quality management for
patients with CAD in clinical practice.
This study has limitations. It was a retrospective, single center,
relatively small size investigation. However, the number of
patients in our study was 483, although it was a single center
study, and was larger than that (n = 314) in the COURAGE Nuclear
Sub-study [8], which provided evidence in nuclear cardiology, and
also was comparable to the target number of patients (n = 500) in
another multicenter prospective study (J-ACCESS 4) [18].
In conclusion, myocardial ischemic reduction leads to decrease
MCE rates after treatment such as revascularization. Quantitative
assessment of myocardial ischemic reduction by serial nuclear
cardiology studies is useful for prediction of prognosis in Japanese
patients with CAD.
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